Thales, the final Brilinta outcome trial in Astrazeneca’s huge Parthenon programme, has hit – but the UK group’s vast investment in its blood thinner has yet to pay off.
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020.
The second half of 2019 saw half as many innovative medical devices approved as the first.
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Amgen's aggressive legal pursuit of Sanofi and Regeneron's Praluent might work, but will the PCSK9 developers ever recoup their costs?
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.